Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Salix gains new rights as rifaximin deal with Alfa restructured

This article was originally published in Scrip

Executive Summary

Salix Pharmaceuticals is again seeking new lines of revenue from its top-selling product, Xifaxan (rifaximin) for traveller's diarrhoea and hepatic encephalopathy, most recently by renegotiating with Alfa Wasserman Salix's North American rights to rifaximin to include an extended intestinal release (EIR) formulation in gastrointestinal and respiratory indications, including Crohn's disease, for $10 million upfront.

You may also be interested in...



Biogen’s Tau Antibody Fails In PSP, But Alzheimer’s Studies Continue

Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing. 

Finance Watch: IPOs Are In A Slump, But Already Public Companies Have Rallied

Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m. 

Finance Watch: Omega, Perceptive/Xontogeny Raise $648m For Life Science Investments

Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.

Topics

Related Companies

UsernamePublicRestriction

Register

SC018442

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel